Outcomes | Number of studies |
---|---|
Clinical | 62 |
Complete or partial response | 23 |
Clinical remission | 10 |
Symptoms resolution | 10 |
Relapse | 7 |
Time to development of attacks | 4 |
Time to resolution of attacks | 4 |
Clinical response | 3 |
AIDAI | 3 |
Reduction in attack frequency | 3 |
Change in attack length | 2 |
Clinical improvement | 1 |
Biochemical markers | 40 |
CRP | 34 |
SAA | 26 |
ESR | 17 |
Biochemical remission/response | 2 |
Haemoglobin | 2 |
Platelet count | 2 |
Mevalonic acid | 1 |
Patient reported outcomes | 23 |
PhGA | 17 |
PtGA | 9 |
HRQoL | |
SF-36 | 3 |
CHAQ/HAQ | 3 |
CHQ-PF50 | 3 |
FACIT-F | 1 |
DLQI | 1 |
RAND-36 | 1 |
Not reported | 1 |
Safety | 35 |
Others | 12 |
Hearing-related | 9 |
Neurological | 5 |
Visual | 4 |
Pregnancy-related | 1 |
Musculoskeletal | 1 |
Switching between anti-IL-1 agents | 13 |
From anakinra to canakinumab | 11 |
Canakinumab to anakinra | 3 |
AIDAI, Auto-inflammatory Disease Activity Index; CHAQ, Child Health Assessment Questionnaire; CHQ-PF50, Child Health Assessment Questionnaire—Parent Form; CRP, C reactive protein; DLQI, Dermatology Life Quality Investigation; ESR, erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HRQoL, health-related quality of life; IL-1, interleukin 1; PhGA, Physician assessed Global assessment of disease; PtGA, patient/parent assessed Global assessment of disease; RAND-36, RAND-36 Health Survey; SAA, serum amyloid A; SF-36, 36-item Short-Form Health Survey.